Job Description
Build our future together:
The Neurology Account Director (NAD) is a field-based institutional key account role responsible for driving the launch and ongoing commercial performance of Regeneron's C5 inhibitor for generalized myasthenia gravis (gMG) within approximately 10 - 12 assigned academic medical centers (AMCs) infusion centers, and neuromuscular specialty centers. The account director serves as a Regeneron commercial point of contact within targeted institutions, responsible for formulary access, infusion suite education and pull-through, and long-term institutional partnership development. The AD combines deep MG clinical acumen, institutional navigation skills, financial acumen, and cross-functional coordination to maximize patient access and revenue within their assigned territory.
When & where:
The Neurology Account Director (NAD) is a field-based institutional key account role responsible for driving the launch and ongoing commercial performance of Regeneron's C5 inhibitor for generalized myasthenia gravis (gMG) within approximately 10 - 12 assigned academic medical centers (AMCs) infusion centers, and neuromuscular specialty centers. The account director serves as a Regeneron commercial point of contact within targeted institutions, responsible for formulary access, infusion suite education and pull-through, and long-term institutional partnership development. The AD combines deep MG clinical acumen, institutional navigation skills, financial acumen, and cross-functional coordination to maximize patient access and revenue within their assigned territory.
When & where:
- Remote role
- Location: New York Metro, New Jersey, Pennsylvania, Maryland, Washington DC
- Travel: Up to 60-70%, inclu...
Ready to Apply?
Submit your application today and join our talented team at Regeneron Pharmaceuticals.
Submit ApplicationJob Details
- Location Remote, Remote
- Job Type Full-time
- Category Healthcare Practitioners and Technical Occupations
- Posted Date July 03, 2026
- Application Deadline August 12, 2026